Genzeva's publishes the first two papers incorporating Multiomics and Digital Twin

Genzeva, an early stage biotech company, is revolutionizing drug development with its patent-pending process integrating Multiomics and Digital Twins to more clearly understand the pathophysiology of disease(s) and to identify new therapeutic targets.

Multiomics and "digital twins" are combined in the field of healthcare to create highly detailed virtual representations of individuals by integrating vast amounts of biological data from various "omics" like genomics, proteomics, metabolomics, and more, allowing for personalized predictions and simulations related to disease progression, treatment response, and potential health risks, essentially creating a "digital twin" of a patient based on their comprehensive biological profile.

In a groundbreaking move, the company has recently published the first peer-reviewed papers utilizing Digital Twins in biomedical research. The papers delve into the intricacies of knowledge engineering through a Biomimetic Digital Twin Ecosystem, Phenotype-Driven Variant Analysis, and Exome Sequencing to unravel the molecular mechanisms of diseases.

One of the published papers by Kearns WG, et al., sheds light on the application of this innovative approach in understanding disease pathology. Titled "The Application of Knowledge Engineering via the Use of a Biomimetic Digital Twin Ecosystem," the research was published in J Mol Diagn, showcasing significant advancements in the field (DOI: 10.1016/j.jmoldx.2024.03.004).

Another paper by Kearns WG, et al., explores the potential reclassification of variants of unknown clinical significance in Rheumatoid Arthritis using Biomimetic Digital Twins and Multiomics. This cutting-edge research is currently in press at J Mol Diagn, promising new insights into disease classification and treatment strategies.

Genzeva's pioneering work in leveraging Multiomics and Digital Twins marks a significant milestone in biotech research, opening new avenues for precision medicine and targeted therapies.